Human Immunodeficiency Virus (HIV)
82
10
11
53
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
21 trials with published results (26%)
Research Maturity
53 completed trials (65% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
6.1%
5 terminated out of 82 trials
91.4%
+4.8% vs benchmark
15%
12 trials in Phase 3/4
40%
21 of 53 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 53 completed trials
Clinical Trials (82)
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)
The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)
Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
The Trans-Led Care Study
Vitamin D3 Supplementation in Patients With HIV: Effects on Interleukin-6 Levels and CD4 Counts
HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning Clinics
C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States
ComBaCaL HIV Prevention TwiCs
Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIV
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
Persuasive Health Communication Intervention for HIV/HCV
Voluntary HIV Screening in the General Population in France
Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Reducing Systemic Inflammation in People on Antiretroviral Therapy
An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study